A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.

Summary

The purpose of this study is to assess the safety and tolerability of a dose of 95μg sNN0031 after intracerebroventricular administration to patients with Parkinson's disease

Timeline

Start

2013-04

Primary completion

2015-10

Completion

2015-10

Outcome

Outcome not reported

Stopped: “Issues with development and supply of infusion system for delivery of IMP. Prolonged approval process for the clinical study sNN0031-004.”

Drugs

Indications